Does the media favor AXSM or ETON?

In the previous week, Axsome Therapeutics and Axsome Therapeutics both had 20 articles in the media. Eton Pharmaceuticals' average media sentiment score of 0.49 beat Axsome Therapeutics' score of 0.24 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Eton Pharmaceuticals 5 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AMRX or ETON?

In the previous week, Eton Pharmaceuticals had 13 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 20 mentions for Eton Pharmaceuticals and 7 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.71 beat Eton Pharmaceuticals' score of 0.49 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Eton Pharmaceuticals 5 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LNTH or ETON?

In the previous week, Eton Pharmaceuticals had 14 more articles in the media than Lantheus. MarketBeat recorded 20 mentions for Eton Pharmaceuticals and 6 mentions for Lantheus. Lantheus' average media sentiment score of 0.87 beat Eton Pharmaceuticals' score of 0.49 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eton Pharmaceuticals 5 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ETON or BLTE?

In the previous week, Eton Pharmaceuticals had 1 more articles in the media than Belite Bio. MarketBeat recorded 20 mentions for Eton Pharmaceuticals and 19 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.63 beat Eton Pharmaceuticals' score of 0.49 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 5 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Belite Bio 2 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ETON or MANE?

In the previous week, Veradermics had 4 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 24 mentions for Veradermics and 20 mentions for Eton Pharmaceuticals. Veradermics' average media sentiment score of 0.86 beat Eton Pharmaceuticals' score of 0.49 indicating that Veradermics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 5 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Veradermics 9 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Eton Pharmaceuticals (ETON) Competitors

$63.93 +2.48 (+4.04%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$63.25 -0.68 (-1.06%)

As of 11/13/2026 07:58 PM Eastern

Compare

ETON vs. AXSM, AMRX, LNTH, BLTE, and MANE

Should you buy Eton Pharmaceuticals stock or one of its competitors? Eton Pharmaceuticals's main competitors and comparable companies include Axsome Therapeutics (AXSM), Amneal Pharmaceuticals (AMRX), Lantheus (LNTH), Belite Bio (BLTE), and Veradermics (MANE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Eton Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Eton Pharmaceuticals (NASDAQ:ETON) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Axsome Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Eton Pharmaceuticals has a net margin of 35.35% compared to Axsome Therapeutics' net margin of -18.18%. Eton Pharmaceuticals' return on equity of 104.82% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-18.18%	-198.73%	-22.03%
Eton Pharmaceuticals	35.35%	104.82%	43.09%

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Eton Pharmaceuticals has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	11.67	-$183.17M	-$3.06	N/A
Eton Pharmaceuticals	$79.95M	23.06	-$4.60M	$1.51	42.34

In the previous week, Axsome Therapeutics and Axsome Therapeutics both had 20 articles in the media. Eton Pharmaceuticals' average media sentiment score of 0.49 beat Axsome Therapeutics' score of 0.24 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	5 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Axsome Therapeutics currently has a consensus price target of $266.21, suggesting a potential upside of 87.88%. Eton Pharmaceuticals has a consensus price target of $79.75, suggesting a potential upside of 24.75%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Axsome Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
Eton Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Eton Pharmaceuticals beats Axsome Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Eton Pharmaceuticals (NASDAQ:ETON) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Amneal Pharmaceuticals has higher revenue and earnings than Eton Pharmaceuticals. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.20B	2.14	$72.06M	$0.42	50.90
Eton Pharmaceuticals	$79.95M	23.06	-$4.60M	$1.51	42.34

Amneal Pharmaceuticals presently has a consensus target price of $23.00, indicating a potential upside of 7.58%. Eton Pharmaceuticals has a consensus target price of $79.75, indicating a potential upside of 24.75%. Given Eton Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eton Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Eton Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Amneal Pharmaceuticals has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Eton Pharmaceuticals had 13 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 20 mentions for Eton Pharmaceuticals and 7 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.71 beat Eton Pharmaceuticals' score of 0.49 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Eton Pharmaceuticals	5 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eton Pharmaceuticals has a net margin of 35.35% compared to Amneal Pharmaceuticals' net margin of 4.17%. Amneal Pharmaceuticals' return on equity of 283.50% beat Eton Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.17%	283.50%	7.79%
Eton Pharmaceuticals	35.35%	104.82%	43.09%

Summary

Amneal Pharmaceuticals beats Eton Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Eton Pharmaceuticals (NASDAQ:ETON) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Lantheus has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

In the previous week, Eton Pharmaceuticals had 14 more articles in the media than Lantheus. MarketBeat recorded 20 mentions for Eton Pharmaceuticals and 6 mentions for Lantheus. Lantheus' average media sentiment score of 0.87 beat Eton Pharmaceuticals' score of 0.49 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eton Pharmaceuticals	5 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus currently has a consensus price target of $107.44, indicating a potential upside of 5.76%. Eton Pharmaceuticals has a consensus price target of $79.75, indicating a potential upside of 24.75%. Given Eton Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eton Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.21
Eton Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Lantheus has higher revenue and earnings than Eton Pharmaceuticals. Lantheus is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.56B	4.25	$233.56M	$4.06	25.02
Eton Pharmaceuticals	$79.95M	23.06	-$4.60M	$1.51	42.34

Eton Pharmaceuticals has a net margin of 35.35% compared to Lantheus' net margin of 17.28%. Eton Pharmaceuticals' return on equity of 104.82% beat Lantheus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.28%	29.26%	15.40%
Eton Pharmaceuticals	35.35%	104.82%	43.09%

99.1% of Lantheus shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Eton Pharmaceuticals beats Lantheus on 11 of the 16 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Belite Bio?

Eton Pharmaceuticals (NASDAQ:ETON) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Eton Pharmaceuticals has a net margin of 35.35% compared to Belite Bio's net margin of 0.00%. Eton Pharmaceuticals' return on equity of 104.82% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	35.35%	104.82%	43.09%
Belite Bio	N/A	-9.92%	-9.75%

Eton Pharmaceuticals currently has a consensus target price of $79.75, indicating a potential upside of 24.75%. Belite Bio has a consensus target price of $226.27, indicating a potential upside of 37.68%. Given Belite Bio's higher possible upside, analysts plainly believe Belite Bio is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Eton Pharmaceuticals has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.19, meaning that its stock price is 219% less volatile than the broader market.

Eton Pharmaceuticals has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	23.06	-$4.60M	$1.51	42.34
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

In the previous week, Eton Pharmaceuticals had 1 more articles in the media than Belite Bio. MarketBeat recorded 20 mentions for Eton Pharmaceuticals and 19 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.63 beat Eton Pharmaceuticals' score of 0.49 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	5 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	2 Very Positive mention(s)	6 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Eton Pharmaceuticals beats Belite Bio on 12 of the 15 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Veradermics?

Eton Pharmaceuticals (NASDAQ:ETON) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, Veradermics had 4 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 24 mentions for Veradermics and 20 mentions for Eton Pharmaceuticals. Veradermics' average media sentiment score of 0.86 beat Eton Pharmaceuticals' score of 0.49 indicating that Veradermics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	5 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veradermics	9 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eton Pharmaceuticals presently has a consensus price target of $79.75, indicating a potential upside of 24.75%. Veradermics has a consensus price target of $174.57, indicating a potential upside of 35.14%. Given Veradermics' higher probable upside, analysts plainly believe Veradermics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Eton Pharmaceuticals has a net margin of 35.35% compared to Veradermics' net margin of 0.00%. Eton Pharmaceuticals' return on equity of 104.82% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	35.35%	104.82%	43.09%
Veradermics	N/A	-20.50%	-17.66%

Eton Pharmaceuticals has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	23.06	-$4.60M	$1.51	42.34
Veradermics	N/A	N/A	-$70M	-$1.90	N/A

27.9% of Eton Pharmaceuticals shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Eton Pharmaceuticals beats Veradermics on 9 of the 13 factors compared between the two stocks.

Get Eton Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ETON vs. The Competition

Export

Metric	Eton Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.77B	$13.77B	$7.84B	$12.19B
Dividend Yield	N/A	2.56%	2.46%	4.53%
P/E Ratio	42.34	29.40	34.71	28.44
Price / Sales	23.06	7.34	8.66	5.84
Price / Cash	11,855.61	15.74	21.93	22.49
Price / Book	21.24	4.93	4.35	3.76
Net Income	-$4.60M	$2.88B	$3.51B	$390.55M
7 Day Performance	13.23%	-0.21%	-1.49%	-0.33%
1 Month Performance	20.90%	-3.25%	-2.55%	-4.82%
1 Year Performance	277.39%	-6.14%	0.92%	-5.83%

Eton Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ETON Eton Pharmaceuticals	3.8388 of 5 stars	$63.93 +4.0%	$79.75 +24.7%	+278.7%	$1.77B	$79.95M	42.34	44	Analyst Forecast Insider Trade
AXSM Axsome Therapeutics	3.5619 of 5 stars	$138.14 +3.1%	$267.58 +93.7%	+3.1%	$7.30B	$638.50M	N/A	925	Analyst Forecast Analyst Revision Gap Down
AMRX Amneal Pharmaceuticals	3.6648 of 5 stars	$21.40 +0.5%	$23.00 +7.5%	+85.6%	$6.83B	$3.02B	50.91	8,500	Analyst Downgrade
LNTH Lantheus	2.9244 of 5 stars	$101.54 +0.5%	$107.44 +5.8%	+91.2%	$6.63B	$1.54B	25.00	1,193
BLTE Belite Bio	3.2703 of 5 stars	$157.06 -0.4%	$227.40 +44.8%	+46.2%	$6.33B	N/A	N/A	41	Trending News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ETON) was last updated on 11/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eton Pharmaceuticals (ETON) Competitors

ETON vs. AXSM, AMRX, LNTH, BLTE, and MANE

How does Eton Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Eton Pharmaceuticals compare to Amneal Pharmaceuticals?

Summary

How does Eton Pharmaceuticals compare to Lantheus?

Summary

How does Eton Pharmaceuticals compare to Belite Bio?

Summary

How does Eton Pharmaceuticals compare to Veradermics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eton Pharmaceuticals (ETON) Competitors

ETON vs. AXSM, AMRX, LNTH, BLTE, and MANE

How does Eton Pharmaceuticals compare to Axsome Therapeutics?

Which has more risk and volatility, AXSM or ETON?

Is AXSM or ETON more profitable?

Do insiders and institutionals hold more shares of AXSM or ETON?

Which has better valuation & earnings, AXSM or ETON?

Does the media favor AXSM or ETON?

Do analysts rate AXSM or ETON?

Summary

How does Eton Pharmaceuticals compare to Amneal Pharmaceuticals?

Which has stronger valuation and earnings, AMRX or ETON?

Do analysts rate AMRX or ETON?

Which has more risk & volatility, AMRX or ETON?

Do institutionals & insiders believe in AMRX or ETON?

Does the media refer more to AMRX or ETON?

Is AMRX or ETON more profitable?

Summary

How does Eton Pharmaceuticals compare to Lantheus?

Which has more volatility and risk, LNTH or ETON?

Does the media prefer LNTH or ETON?

Do analysts prefer LNTH or ETON?

Which has higher earnings and valuation, LNTH or ETON?

Is LNTH or ETON more profitable?

Do insiders & institutionals believe in LNTH or ETON?

Summary

How does Eton Pharmaceuticals compare to Belite Bio?

Is ETON or BLTE more profitable?

Do analysts recommend ETON or BLTE?

Do institutionals and insiders believe in ETON or BLTE?

Which has more risk and volatility, ETON or BLTE?

Which has stronger earnings and valuation, ETON or BLTE?

Does the media favor ETON or BLTE?

Summary

How does Eton Pharmaceuticals compare to Veradermics?

Does the media favor ETON or MANE?

Do analysts prefer ETON or MANE?

Is ETON or MANE more profitable?

Which has stronger earnings & valuation, ETON or MANE?

Do institutionals & insiders believe in ETON or MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools